Efficient systemic treatment of dystrophic muscle pathologies
US10166272B2 · kind B2 · utility
11Cited by
0References
12Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 24, 2015 |
| Grant date | Jan 1, 2019 |
| Priority date | — |
| Expiry date | Apr 24, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2840/007
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A composition comprising a gene therapy product for use in the treatment of a dystrophic disease in a subject, advantageously in humans, wherein: —the gene therapy product comprises a nucleic acid sequence encoding a functional microdystrophin; —the composition is systemically administered.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.